SCHEMBL5545867

SCHEMBL5545867

[CH2]c1ccc(Oc2ccc(Br)cc2F)cc1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 1/20 0.41
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
SLC6A4 P31645 5/20 0.39
SLC6A2 P23975 1/20 0.37
SLC6A3 Q01959 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
TSHR P16473 2/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
HTR6 P50406 1/20 0.35
MAPT P10636 2/20 0.34
GAA P10253 1/20 0.34
PTGS2 P35354 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10561428 0.82 MAPT (0.57) HSPB1ALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL9762780 0.82 MEN1 (0.45) HSPB1ALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL1129244 0.81 SLC6A4 (0.50) HSPB1ALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL27266032 0.80 MAPK1 (0.58) ALDH1A1MAPK1TDP1L3MBTL1SLC6A4
SCHEMBL10543538 0.79 MAPT (0.38) HSPB1ALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL30760842 0.79 MET (0.41) HSPB1ALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL9762708 0.78 TTR (0.42) HSPB1ALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL2187107 0.76 GRM2 (0.39) ALDH1A1MAPK1TDP1L3MBTL1SLC6A4
SCHEMBL10564929 0.76 HSPB1 (0.73) HSPB1ALDH1A1POLBHTTMAPT
SCHEMBL31287820 0.76 HSPB1 (0.73) HSPB1ALDH1A1POLBHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 HSPB1 1523/4885ALDH1A1 355/4885MAPK1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.